A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer

By afschroeder • August 15, 2025

Cummings AL, Sussell J, Rosettie KL, Moustaid FE, Ogale S, Ngiam C, Jovanoski N, Arnold M, Lee JM. A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer. Lung Cancer. 2025 Aug 6;207:108701. doi: 10.1016/j.lungcan.2025.108701. Epub ahead of print. PMID: 40811940.

Tags: Alectinib, anaplastic lymphoma kinase, chemotherapy, Costs and Cost Analysis, Hematology/Oncology, Non-small cell lung cancer, Publications, Pulmonary, Critical Care & Sleep Medicine, Statistical model, Tyrosine kinase inhibitors

Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE

Rugo HS, Tolaney SM, Chan N, Borges G, Yerushalmi R, Sharifi MN, McHayleh W, Beck T, Vidula N, Hamilton E, Rinn KJ, O'Shaughnessy J, Curigliano[...]

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial

Le X, Passaro A, Zhao Y, Huang Y, Laskin J, Rodriguez-Abreu D, Calles A, Bazhenova L, Lo Russo G, Leighl NB, Cappuzzo F, Girard N,[...]

Novel Endocrine Therapies: Current Status and Future Directions

Brierley-Green E, Duggirala N, McCann KE, Callahan R, Bardia A, Lipsyc-Sharf M. Novel Endocrine Therapies: Current Status and Future Directions. Clin Breast Cancer. 2026 Aug[...]